Videos

5 experts in this video

Panelists discuss how health care professionals use standardized antibody-drug conjugate (ADC) pathways to guide dosing, adverse effect (AE) management, and transitions. Protocols ensure monitoring, toxicity mitigation, and seamless shifts between therapies for optimal care.

5 experts in this video

Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.

A panelist discusses how the 505(b)(2) regulatory pathway provides a streamlined approval process for modified versions of previously approved drugs, allowing pharmaceutical companies to rely partly on existing safety/efficacy data while still requiring new clinical data, commonly used across various therapeutic areas including reformulations, new dosage forms, and drug combinations.

5 experts in this video

Panelists discuss how health care professionals support medication adherence through personalized strategies, communication, and technological aids, while evaluating menopause therapy effectiveness via regular assessments, standardized tools, and comprehensive patient-centered approaches.

5 experts in this video

Panelists note how medical professionals discuss menopause therapy, addressing symptoms, treatment options, safety concerns, adverse events, and personalized management strategies through patient-centered care. Professionals prioritize transparent communication, comprehensive risk assessment, and collaborative decision-making to ensure patient comfort and optimal management of menopausal transition.

5 experts in this video

Panelists discuss how antibody-drug conjugates (ADCs) often show more diverse outcomes in real-world settings compared with clinical trials, with varying efficacy and adverse effect profiles. Key practical considerations for pharmacists include appropriate dosing based on patient factors, managing drug interactions, implementing premedication protocols to minimize adverse reactions, and providing comprehensive supportive care. Careful monitoring and individualized patient management are essential for optimal therapeutic outcomes.

5 experts in this video

Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.

5 experts in this video

Panelists discuss how emerging antibody-drug conjugates (ADCs) in metastatic breast cancer (mBC) treatment demonstrate innovation through optimized drug-to-antibody ratios, novel payloads, and targeted approaches to different breast cancer subtypes. Key trials explore combinations with established therapies and potential for improved tolerability profiles. Additional notable studies include comparative effectiveness research between approved ADCs and investigation of biomarker-driven patient selection strategies to maximize therapeutic benefit while minimizing adverse effects.

5 experts in this video

Panelists discuss how health care professionals recommend lifestyle modifications, dietary changes, and OTC products to manage menopause symptoms, focusing on exercise, nutrition, stress reduction, and targeted supplements to support overall well-being during this transitional period.